Eric Dube, Travere Therapeutics CEO
May 26, 2021 09:39 AM EDT
FDA+

Tra­vere takes a hit as FDA staffers shoo off their ac­cel­er­at­ed drug pitch

John Carroll

Editor & Founder

Three months af­ter the ex­ecs at Tra­vere Ther­a­peu­tics $TVTX picked up in­ter­im da­ta for its treat­ment for a rare kid­ney dis­ease and made a bee­line …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: Vi­jay Pande hands a16z biotech lead­er­ship to Vi­nee­ta Agar­wala, moves to AI role

Po­lice ar­rest per­son of in­ter­est in con­nec­tion with killing of Unit­ed­Health­care CEO

ADC sci­en­tist who paved the way for Dai­ichi’s En­her­tu dies

Trump el­e­vates dis­proven link be­tween vac­cines and autism, say­ing ‘some­thing is go­ing on’

Agios' stock drops af­ter dis­clos­ing new liv­er-re­lat­ed safe­ty warn­ing in fil­ing to FDA

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times